Ikena Oncology Inc IKNA.OQ IKNA.O is expected to show a fall in quarterly revenue when it reports results on May 12 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Ikena Oncology Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ikena Oncology Inc is $3.00, above its last closing price of $1.43.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.25 | -0.27 | -0.21 | Beat | 21.3 |
Jun. 30 2024 | -0.33 | -0.35 | -0.28 | Beat | 19.4 |
Mar. 31 2024 | -0.41 | -0.41 | -0.33 | Beat | 20 |
Dec. 31 2023 | -0.43 | -0.47 | Missed | -9.8 | |
Sep. 30 2023 | -0.42 | -0.43 | -0.40 | Beat | 7 |
Jun. 30 2023 | -0.46 | -0.47 | -0.44 | Beat | 7.3 |
Mar. 31 2023 | -0.47 | -0.47 | -0.39 | Beat | 16.6 |
Dec. 31 2022 | -0.53 | -0.48 | -0.40 | Beat | 16.1 |
This summary was machine generated March 7 at 12:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。